Лимфома Беркитта: клиника, диагностика, лечение

Е А Барях, С К Кравченко, Т. Н. Обухова et al. · Клиническая онкогематология. Фундаментальные исследования и клиническая практика · 2009

Burkitts lymphoma (BL) is the most aggressive B-cell lymphoid neoplasm, which growth fraction approximates 100%. BL has specific chromosomal abnormalities (t(8;14)(q24;q32), rarely t(2;8)(p12;q32), t(8;22)(q24;q11)). Three clinical variants of BL are recognized (endemic, sporadic and immunodeficiency-associated BL), each manifesting differences in clinical presentation, morphology and biology. Extranodal sites are most often involved with some variation according to the clinical variants. In all three clinical variants patients are at risk for central nervous system and bone marrow involvement. BL patients are staged according to the system of S.B. Murphy. 80% of patients present at advanced stages (III, IV or L3 B-ALL). Dеspite the rapid proliferative rate, BL is one of the most chemosensitive lymphoid neoplasm. The intensification and shorter treatment duration of chemotherapy allowed the remissions in 85-90% cases and increased 5-year survival up to 60-65% (depending on the stage of the disease). Several pediatric regimens have been quite successful in the treatment of adult cases of BL. New short-term high-intensive protocols LMB and CODOX-M/IVAC made it possible to obtain much better results compared with less intensive protocols. However, these results were worse than those in children. This fact can be accounted for by the more frequent bone marrow and CNS involvement and different drug metabolism in adults which increases toxicity of intensive chemotherapy regimens. 37 patients participated in the study performed in the Russian Hematological Research Center between August 2003 and December 2008. The treatment was based on experimental high intensive protocol BL-M-04. The 5-year disease-free survival was 97% with 5-year overall survival of 89%. The use of this protocol can achieve rapid tumor regression with a short treatment duration due to chemotherapy intensification and acceptable toxicity. Unfavorable prognostic factors, which require intensive treatment include the following: age > 15 years, female sex, elevated serum LDH, bone marrow and CNS involvement, bulky disease, high International Prognostic Index (IPI).

Cited by 0 works.

Authors